• Zentalis Pharmaceuticals flagged new Phase 1b results for its WEE1 inhibitor azenosertib with paclitaxel in platinum-resistant ovarian cancer, slated for presentation at the ASCO annual meeting on June 1, 2026.
• The combination produced signs of meaningful tumor shrinkage and durable disease control in a heavily pre-treated population, with activity described as encouraging versus historical expectations for paclitaxel alone.
• Safety was characterized as manageable across dose groups, with side effects largely consistent with chemotherapy-based regimens and a limited rate of severe events.
• A 250 mg intermittent schedule was highlighted as a potential preferred regimen based on the balance of activity and tolerability.
• The readout supports Zentalis’ broader indication-expansion strategy for azenosertib combinations, alongside its registration-focused monotherapy program in Cyclin E1-positive platinum-resistant ovarian cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001725160-26-000045), on May 21, 2026, and is solely responsible for the information contained therein.